Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb is projected to generate nearly $860mn in adjusted earnings before interest, taxation, depreciation and ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

A sale could value Bausch + Lomb at more than $13 billion, according to Bloomberg Intelligence analyst Mike Holland. The news is “certainly welcome to investors tied up in the Gordian’s knot at Bausch ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...